Jenny Pena Dias1, Sabina A Haberlen2, Adrian S Dobs1, Jordan E Lake3, Frank J Palella4, Lawrence A Kingsley5, Jennifer C Price6, Shehzad Basaria7, Ravi Varadhan8, Joseph B Margolick9, Chloe L Thio1, Todd T Brown1. 1. Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD. 2. Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD. 3. Division of Infectious Diseases, McGovern School of Medicine, Houston, TX. 4. Division of Infectious Disease, Feinberg School of Medicine, Northwestern University, Chicago, IL. 5. Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA. 6. Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, San Francisco, CA. 7. Section on Men's Health, Aging and Metabolism, Brigham and Women's Hospital Harvard Medical School, Boston, MA. 8. Department of Oncology; Biostatistics and Bioinformatics, Johns Hopkins University, Baltimore, MD; and. 9. Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD.
Abstract
BACKGROUND: Sex hormone-binding globulin (SHBG) is a glycoprotein that regulates sex hormone bioavailability and increases with age in the general population. SHBG concentrations are higher in people with HIV, a population in whom accelerated aging has been hypothesized. It is unclear whether longitudinal changes in SHBG increase over time and differ by HIV serostatus. METHODS: In a longitudinal study, SHBG was measured in 182 men with HIV (MWH) and 267 men without HIV (seronegative) from the Multicenter AIDS Cohort Study and matched for age, race, site, and time, with ≥2 SHBG serum samples over the 10 years after HAART initiation. Multivariable linear mixed-effects regression models were used to evaluate whether log-transformed SHBG [ln(SHBG)] and its rate of change differed by HIV serostatus. RESULTS: At baseline, the mean age in MWH was similar to that in HIV-seronegative men (51 ± 5 vs 49 ± 6 years). However, SHBG mean values were higher in MWH compared with those in HIV-seronegative men (65.6 ± 48.8 vs. 45.4 ± 22 nmol/L, P < 0.001). In a fully adjusted model, SHBG increased over time and at a faster rate in MWH compared with that in HIV-seronegative men: [2.0%/year (95% CI: 1.4 to 2.7) vs 1.3%/year (95% CI: 0.8 to 1.8), respectively, P = 0.038]. Among MWH, higher SHBG concentrations were significantly associated with lower CD4+ T-cell count [β= -0.02 (95% CI: -0.03 to -0.0002), P < 0.05], fewer cumulative years on zidovudine [β = -0.027 (95% CI: -0.045 to -0.009), P < 0.001], and greater cumulative years on nonnucleoside reverse transcriptase inhibitors drugs [β = 0.022 (95% CI: 0.0006 to 0.04), P < 0.05]. CONCLUSIONS: Aging-related increases in SHBG were faster in MWH compared with those in HIV-seronegative men and were related to poorer immunologic status and antiretroviral medication exposure. The mechanisms and consequences of these findings require further investigation.
BACKGROUND: Sex hormone-binding globulin (SHBG) is a glycoprotein that regulates sex hormone bioavailability and increases with age in the general population. SHBG concentrations are higher in people with HIV, a population in whom accelerated aging has been hypothesized. It is unclear whether longitudinal changes in SHBG increase over time and differ by HIV serostatus. METHODS: In a longitudinal study, SHBG was measured in 182 men with HIV (MWH) and 267 men without HIV (seronegative) from the Multicenter AIDS Cohort Study and matched for age, race, site, and time, with ≥2 SHBG serum samples over the 10 years after HAART initiation. Multivariable linear mixed-effects regression models were used to evaluate whether log-transformed SHBG [ln(SHBG)] and its rate of change differed by HIV serostatus. RESULTS: At baseline, the mean age in MWH was similar to that in HIV-seronegative men (51 ± 5 vs 49 ± 6 years). However, SHBG mean values were higher in MWH compared with those in HIV-seronegative men (65.6 ± 48.8 vs. 45.4 ± 22 nmol/L, P < 0.001). In a fully adjusted model, SHBG increased over time and at a faster rate in MWH compared with that in HIV-seronegative men: [2.0%/year (95% CI: 1.4 to 2.7) vs 1.3%/year (95% CI: 0.8 to 1.8), respectively, P = 0.038]. Among MWH, higher SHBG concentrations were significantly associated with lower CD4+ T-cell count [β= -0.02 (95% CI: -0.03 to -0.0002), P < 0.05], fewer cumulative years on zidovudine [β = -0.027 (95% CI: -0.045 to -0.009), P < 0.001], and greater cumulative years on nonnucleoside reverse transcriptase inhibitors drugs [β = 0.022 (95% CI: 0.0006 to 0.04), P < 0.05]. CONCLUSIONS: Aging-related increases in SHBG were faster in MWH compared with those in HIV-seronegative men and were related to poorer immunologic status and antiretroviral medication exposure. The mechanisms and consequences of these findings require further investigation.
Authors: Nikolas Itaru Wada; Lisa P Jacobson; Joseph B Margolick; Elizabeth Crabb Breen; Bernard Macatangay; Sudhir Penugonda; Otoniel Martínez-Maza; Jay H Bream Journal: AIDS Date: 2015-02-20 Impact factor: 4.177
Authors: Monika Eichholzer; Aline Barbir; Shehzad Basaria; Adrian S Dobs; Manning Feinleib; Eliseo Guallar; Andy Menke; William G Nelson; Nader Rifai; Elizabeth A Platz; Sabine Rohrmann Journal: Aging Male Date: 2012-07-23 Impact factor: 5.892
Authors: Kristine M Erlandson; Amanda A Allshouse; Catherine M Jankowski; Eric J Lee; Kevin M Rufner; Brent E Palmer; Cara C Wilson; Samantha MaWhinney; Wendy M Kohrt; Thomas B Campbell Journal: J Infect Dis Date: 2013-04-04 Impact factor: 5.226
Authors: Majon Muller; Isolde den Tonkelaar; Jos H H Thijssen; Diederick E Grobbee; Yvonne T van der Schouw Journal: Eur J Endocrinol Date: 2003-12 Impact factor: 6.664
Authors: Anne K Monroe; Adrian S Dobs; Frank J Palella; Lawrence A Kingsley; Mallory D Witt; Todd T Brown Journal: AIDS Res Ther Date: 2014-01-22 Impact factor: 2.250
Authors: Lindsey J Anderson; Dorota Migula; Rebecca Abay; Stephanie Crabtree; Solomon A Graf; Alvin M Matsumoto; Thomas R Chauncey; Jose M Garcia Journal: Andrology Date: 2021-11-25 Impact factor: 3.842
Authors: L Antonio; D Vanderschueren; N Narinx; K David; J Walravens; P Vermeersch; F Claessens; T Fiers; B Lapauw Journal: Cell Mol Life Sci Date: 2022-10-07 Impact factor: 9.207